CLIMB BIO, INC. Comprehensive Income
CLIMB BIO, INC. (CLYM) reported Comprehensive Income of -$13.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$13.72M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$14.00M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$17.55M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$12.74M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$59.44M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$73.87M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$34.76M.
- CLIMB BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$45.48M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.72M 10-Q · filed 2026-08-06 | -$27.72M 10-Q · filed 2026-08-06 | -$45.27M derived: sum of 3 quarters · filed 2026-08-06 | -$58.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$14.00M 10-Q · filed 2026-05-07 | -$31.55M derived: sum of 2 quarters · filed 2026-05-07 | -$44.29M derived: sum of 3 quarters · filed 2026-05-07 | -$52.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$17.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$30.29M derived: sum of 2 quarters · filed 2026-03-05 | -$38.92M derived: sum of 3 quarters · filed 2026-08-06 | -$59.44M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$12.74M 10-Q · filed 2025-11-06 | -$21.37M derived: sum of 2 quarters · filed 2026-08-06 | -$41.89M 10-Q · filed 2025-11-06 | -$50.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$8.63M 10-Q · filed 2026-08-06 | -$29.15M 10-Q · filed 2026-08-06 | -$37.75M derived: sum of 3 quarters · filed 2026-08-06 | -$46.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$20.52M 10-Q · filed 2026-05-07 | -$29.11M derived: sum of 2 quarters · filed 2026-05-07 | -$37.81M derived: sum of 3 quarters · filed 2026-05-07 | -$92.69M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$17.29M derived: sum of 2 quarters · filed 2026-03-05 | -$72.18M derived: sum of 3 quarters · filed 2026-03-05 | -$73.87M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$8.69M 10-Q · filed 2025-11-06 | -$63.58M derived: sum of 2 quarters · filed 2025-11-06 | -$65.28M 10-Q · filed 2025-11-06 | -$68.91M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$54.89M 10-Q · filed 2025-08-12 | -$56.58M 10-Q · filed 2025-08-12 | -$60.22M derived: sum of 3 quarters · filed 2025-08-12 | -$64.16M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$1.70M 10-Q · filed 2025-05-14 | -$5.33M derived: sum of 2 quarters · filed 2025-05-14 | -$9.27M derived: sum of 3 quarters · filed 2025-05-14 | -$14.43M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$7.58M derived: sum of 2 quarters · filed 2025-03-25 | -$12.74M derived: sum of 3 quarters · filed 2025-03-25 | -$34.76M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$3.94M 10-Q · filed 2024-11-12 | -$9.10M derived: sum of 2 quarters · filed 2024-11-12 | -$31.13M 10-Q · filed 2024-11-12 | -$38.67M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$5.16M 10-Q · filed 2024-08-14 | -$27.19M 10-Q · filed 2024-08-14 | -$34.73M derived: sum of 3 quarters · filed 2024-08-14 | -$44.38M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$22.03M 10-Q · filed 2024-05-15 | -$29.57M derived: sum of 2 quarters · filed 2024-05-15 | -$39.23M derived: sum of 3 quarters · filed 2024-05-15 | -$53.90M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$17.20M derived: sum of 2 quarters · filed 2024-03-28 | -$31.88M derived: sum of 3 quarters · filed 2024-03-28 | -$45.48M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$9.66M 10-Q · filed 2023-11-14 | -$24.34M derived: sum of 2 quarters · filed 2023-11-14 | -$37.94M 10-Q · filed 2023-11-14 | -$48.59M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$14.68M 10-Q · filed 2023-08-10 | -$28.28M 10-Q · filed 2023-08-10 | -$38.93M derived: sum of 3 quarters · filed 2023-08-10 | -$48.56M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$13.60M 10-Q · filed 2023-05-11 | -$24.25M derived: sum of 2 quarters · filed 2023-05-11 | -$33.88M derived: sum of 3 quarters · filed 2023-05-11 | -$42.60M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$10.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$20.28M derived: sum of 2 quarters · filed 2023-03-06 | -$29.00M derived: sum of 3 quarters · filed 2023-03-06 | -$47.60M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$9.63M 10-Q · filed 2022-11-14 | -$18.35M derived: sum of 2 quarters · filed 2022-11-14 | -$36.95M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$8.72M 10-Q · filed 2022-08-15 | -$27.32M 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |